-
1
-
-
84872678419
-
Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells
-
Akagi H, Higuchi H, Sumimoto H, et al (2013). Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer, 16, 100-10.
-
(2013)
Gastric Cancer
, vol.16
, pp. 100-110
-
-
Akagi, H.1
Higuchi, H.2
Sumimoto, H.3
-
2
-
-
65549096830
-
Mcl-1 is required for melanoma cell resistance to anoikis
-
Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009). Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res, 7, 549-56.
-
(2009)
Mol Cancer Res
, vol.7
, pp. 549-556
-
-
Boisvert-Adamo, K.1
Longmate, W.2
Abel, E.V.3
Aplin, A.E.4
-
3
-
-
75549084068
-
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts
-
Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A (2009). MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol, 187, 429-42.
-
(2009)
J Cell Biol
, vol.187
, pp. 429-442
-
-
Brunelle, J.K.1
Ryan, J.2
Yecies, D.3
Opferman, J.T.4
Letai, A.5
-
4
-
-
40749122965
-
Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis
-
Chetoui N, Sylia K, Gagnon-Houde JV, et al (2008). Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res, 6, 42-52.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 42-52
-
-
Chetoui, N.1
Sylia, K.2
Gagnon-Houde, J.V.3
-
5
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talaly P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talaly, P.2
-
6
-
-
77953683945
-
Non-viral nanosystems for systemic siRNA delivery
-
David S, Pitard B, Benoit JP, Passirani C (2010). Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res, 62, 100-14.
-
(2010)
Pharmacol Res
, vol.62
, pp. 100-114
-
-
David, S.1
Pitard, B.2
Benoit, J.P.3
Passirani, C.4
-
7
-
-
84856270102
-
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
-
Glaser SP, Lee EF, Trounson E, et al (2012). Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev, 26, 120-5.
-
(2012)
Genes Dev
, vol.26
, pp. 120-125
-
-
Glaser, S.P.1
Lee, E.F.2
Trounson, E.3
-
8
-
-
84878445414
-
Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NFkappaB activity
-
Han P, Luan Y, Lin Y, et al (2013). Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NFkappaB activity. Mol Cell Biochem, 379, 171-80.
-
(2013)
Mol Cell Biochem
, vol.379
, pp. 171-180
-
-
Han, P.1
Luan, Y.2
Lin, Y.3
-
9
-
-
77149178712
-
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs
-
High LM, Szymanska B, WilczynskaI-Kalak U, et al (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol, 77, 483-94.
-
(2010)
Mol Pharmacol
, vol.77
, pp. 483-494
-
-
High, L.M.1
Szymanska, B.2
Wilczynskai-Kalak, U.3
-
10
-
-
34247511009
-
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
-
Hussain SR, Cheney CM, Johnson AJ, et al (2007). Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res, 13, 2144-50.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2144-2150
-
-
Hussain, S.R.1
Cheney, C.M.2
Johnson, A.J.3
-
11
-
-
84863418151
-
Action and reaction: the biological response to siRNA and its delivery vehicles
-
Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012). Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther, 20, 513-24.
-
(2012)
Mol Ther
, vol.20
, pp. 513-524
-
-
Kanasty, R.L.1
Whitehead, K.A.2
Vegas, A.J.3
Anderson, D.G.4
-
12
-
-
67349232739
-
Effectiveness of small interfering RNA (siRNA) against the Mcl-1 gene in a canine mammary gland tumor cell line
-
Kano R, Yano T, Nagamatsu K, et al (2009). Effectiveness of small interfering RNA (siRNA) against the Mcl-1 gene in a canine mammary gland tumor cell line. Res Vet Sci, 87, 64-6.
-
(2009)
Res Vet Sci
, vol.87
, pp. 64-66
-
-
Kano, R.1
Yano, T.2
Nagamatsu, K.3
-
13
-
-
0032006805
-
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
-
Kaufmann SH, Karp JE, Svingen PA, et al (1998). Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91, 991-1000.
-
(1998)
Blood
, vol.91
, pp. 991-1000
-
-
Kaufmann, S.H.1
Karp, J.E.2
Svingen, P.A.3
-
14
-
-
0027480450
-
MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2
-
Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A, 90, 3516-20.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 3516-3520
-
-
Kozopas, K.M.1
Yang, T.2
Buchan, H.L.3
Zhou, P.4
Craig, R.W.5
-
16
-
-
84887572318
-
Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma
-
Li G, Chang H, Zhai YP, Xu W (2013). Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 4943-52.
-
(2013)
Asian Pac J Cancer Prev
, vol.14
, pp. 4943-4952
-
-
Li, G.1
Chang, H.2
Zhai, Y.P.3
Xu, W.4
-
17
-
-
0035710746
-
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method
-
Livaki KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods, 25, 402-8.
-
(2001)
Methods
, vol.25
, pp. 402-408
-
-
Livaki, K.J.1
Schmittgen, T.D.2
-
18
-
-
0030701895
-
Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis
-
Martins LM, Mesner PW, Kottke TJ, et al (1997). Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-96.
-
(1997)
Blood
, vol.90
, pp. 4283-4296
-
-
Martins, L.M.1
Mesner, P.W.2
Kottke, T.J.3
-
19
-
-
34248356003
-
Cellular response to etoposide treatment
-
Montecucco A, Biamonti G (2007). Cellular response to etoposide treatment. Cancer Lett, 252, 9-18.
-
(2007)
Cancer Lett
, vol.252
, pp. 9-18
-
-
Montecucco, A.1
Biamonti, G.2
-
20
-
-
80052777525
-
Targeting Mcl-1 for the therapy of cancer
-
Quinn BA, Dash R, Azab B, et al (2011). Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs, 20, 1397-411.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 1397-1411
-
-
Quinn, B.A.1
Dash, R.2
Azab, B.3
-
21
-
-
84874045787
-
RNA interference as a plausible anticancer therapeutic tool
-
Ramachandran PV, Ignacimuthu S (2012). RNA interference as a plausible anticancer therapeutic tool. Asian Pac J Cancer Prev, 13, 2445-52.
-
(2012)
Asian Pac J Cancer Prev
, vol.13
, pp. 2445-2452
-
-
Ramachandran, P.V.1
Ignacimuthu, S.2
-
22
-
-
59849103061
-
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
-
Reischl D, Zimmer A (2009). Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 5, 8-20.
-
(2009)
Nanomedicine
, vol.5
, pp. 8-20
-
-
Reischl, D.1
Zimmer, A.2
-
23
-
-
74549195798
-
Current and emerging therapies for acute myeloid leukemia
-
Robak T, WierzbowskaI A (2009). Current and emerging therapies for acute myeloid leukemia. Clin Ther, 31, 2349-70.
-
(2009)
Clin Ther
, vol.31
, pp. 2349-2370
-
-
Robak, T.1
Wierzbowska, I.A.2
-
24
-
-
77954386712
-
RNA interference as a gene knockdown technique
-
Shan G (2010). RNA interference as a gene knockdown technique. Int J Biochem Cell Biol, 42, 1243-51.
-
(2010)
Int J Biochem Cell Biol
, vol.42
, pp. 1243-1251
-
-
Shan, G.1
-
25
-
-
48849098719
-
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck
-
Skoda C, Erovic BM, Wachek V, et al (2008). Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep, 19, 1499-503.
-
(2008)
Oncol Rep
, vol.19
, pp. 1499-1503
-
-
Skoda, C.1
Erovic, B.M.2
Wachek, V.3
-
26
-
-
64049106525
-
Immunotherapy of acute myeloid leukemia: current approaches
-
Smits EL, Berneman ZN, Van Tendeloo VF (2009). Immunotherapy of acute myeloid leukemia: current approaches. Oncologist, 14, 240-52.
-
(2009)
Oncologist
, vol.14
, pp. 240-252
-
-
Smits, E.L.1
Berneman, Z.N.2
Van Tendeloo, V.F.3
-
27
-
-
84879377399
-
The prevalent predicament of relapsed acute myeloid leukemia
-
Szer J (2012). The prevalent predicament of relapsed acute myeloid leukemia. Hematol Am Soc Hematol Educ Program, 2012, 43-8.
-
(2012)
Hematol Am Soc Hematol Educ Program
, vol.2012
, pp. 43-48
-
-
Szer, J.1
-
28
-
-
3042570258
-
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide
-
Thallinger C, Wolschek MF, Maierhofer H, et al (2004). Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res, 10, 4185-91.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4185-4191
-
-
Thallinger, C.1
Wolschek, M.F.2
Maierhofer, H.3
-
29
-
-
0038806293
-
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model
-
Thallinger C, Woschek MF, Wacheck V, et al (2003). Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol, 120, 1081-6.
-
(2003)
J Invest Dermatol
, vol.120
, pp. 1081-1086
-
-
Thallinger, C.1
Woschek, M.F.2
Wacheck, V.3
-
30
-
-
42049091619
-
Unique biology of Mcl-1: therapeutic opportunities in cancer
-
Warr MR, Shore GC (2008). Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med, 8, 138-47.
-
(2008)
Curr Mol Med
, vol.8
, pp. 138-147
-
-
Warr, M.R.1
Shore, G.C.2
-
31
-
-
68949111886
-
SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells
-
Xiao J, Yin S, Li Y, et al (2009). SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells. Acta Biochim Biophys Sin, 41, 699-708.
-
(2009)
Acta Biochim Biophys Sin
, vol.41
, pp. 699-708
-
-
Xiao, J.1
Yin, S.2
Li, Y.3
-
32
-
-
36749094533
-
Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs
-
Yang M, Mattes J (2008). Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther, 117, 94-104.
-
(2008)
Pharmacol Ther
, vol.117
, pp. 94-104
-
-
Yang, M.1
Mattes, J.2
-
33
-
-
77951442337
-
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
-
Yecies D, Carlson NE, Deng J, Letai A (2010). Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 115, 3304-13.
-
(2010)
Blood
, vol.115
, pp. 3304-3313
-
-
Yecies, D.1
Carlson, N.E.2
Deng, J.3
Letai, A.4
-
34
-
-
84862638645
-
Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1
-
Zhang S, Li G, Ma X, et al (2012). Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal, 24, 1803-9.
-
(2012)
Cell Signal
, vol.24
, pp. 1803-1809
-
-
Zhang, S.1
Li, G.2
Ma, X.3
|